Cargando…

Effect of peripheral arterial disease on the onset of lactate threshold during cardiopulmonary exercise test: study protocol

INTRODUCTION: Cardiopulmonary exercise test (CPET) is widely used in preoperative assessment and cardiopulmonary rehabilitation. The effect of peripheral arterial disease (PAD) on oxygen delivery (VO(2)) measured by CPET is not known. The aim of this study was to investigate the effect of PAD on VO(...

Descripción completa

Detalles Bibliográficos
Autores principales: Key, Angela, Ali, Tamara, Walker, Paul, Duffy, Nick, Barkat, Mo, Snellgrove, Jayne, Torella, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5168619/
https://www.ncbi.nlm.nih.gov/pubmed/27993904
http://dx.doi.org/10.1136/bmjopen-2016-012763
Descripción
Sumario:INTRODUCTION: Cardiopulmonary exercise test (CPET) is widely used in preoperative assessment and cardiopulmonary rehabilitation. The effect of peripheral arterial disease (PAD) on oxygen delivery (VO(2)) measured by CPET is not known. The aim of this study was to investigate the effect of PAD on VO(2) measurements during CPET. METHODS AND ANALYSIS: We designed a prospective cohort study, which will recruit 30 patients with PAD, who will undergo CPET before and after treatment of iliofemoral occlusive arterial disease. The main outcome measure is the difference in VO(2) at the lactate threshold (LT) between the 2 CPETs. The secondary outcome measure is the relationship between change in VO(2) at the LT and peak exercise pretreatment and post-treatment and haemodynamic measures of PAD improvement (ankle–brachial index differential). For VO(2) changes, only simple paired bivariate comparisons, not multivariate analyses, are planned, due to the small sample size. The correlation between ABI and VO(2) rise will be tested by linear regression. ETHICS AND DISSEMINATION: The study was approved by the North West-Lancaster Research and Ethics committee (reference 15/NW/0801). Results will be disseminated through scientific journal and scientific conference presentation. Completion of recruitment is expected by the end of 2016, and submission for publication by March 2017. TRIAL REGISTRATION NUMBER: NCT02657278.